Trials / Terminated
TerminatedNCT05737706
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- Mirati Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.
Detailed description
This first-in-human clinical trial will begin with an exploration of MRTX1133 dose and regimen. As potentially viable regimens are identified, Phase 1b expansion cohorts may be implemented to ensure collection of sufficient safety and PK information, and early evidence of clinical activity are available to recommend Phase 2 regimens. In Phase 2, separate cohorts of patients by histological diagnosis and/or baseline characteristics will be evaluated for the clinical activity and efficacy of MRTX1133. This study was terminated prior to phase 2 initiating. Only phase 1 of the study was conducted.
Conditions
- Solid Tumor
- Advanced Solid Tumor
- Non-small Cell Lung Cancer
- Colo-rectal Cancer
- Pancreatic Adenocarcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MRTX1133 | KRAS G12D Inhibitor |
Timeline
- Start date
- 2023-03-06
- Primary completion
- 2025-03-10
- Completion
- 2025-03-10
- First posted
- 2023-02-21
- Last updated
- 2025-04-06
Locations
14 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05737706. Inclusion in this directory is not an endorsement.